Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for PFE and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PFE and 80,000+ other tickers.
See exactly how PFE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PFE and 80,000+ other tickers.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables…
Novavax NASDAQ: NVAX executives outlined the company's transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-term attention on Sanofi's commercial rollout of NUVAXOVID, combination vaccine development and early oncology research.
Pfizer (PFE) remains a strong buy as guidance is reaffirmed and raised, with acquired assets compounding at 18% operationally. PFE's pipeline strength is evident, especially in obesity (berobenatide) and Vyndamax, providing a bridge over the 2028 LOE trough. Valuation is highly attractive: P/E of 9.11, EV/EBITDA of 8.29, and a 6.19% dividend yield, with disciplined capital allocation.
California State Teachers Retirement System lifted its holdings in Pfizer Inc. (NYSE: PFE) by 2,320.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 217,981,455 shares of the biopharmaceutical company's stock after purchasing an additional 208,976,273 shares during the quarter. California State
PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.
Collecting $8,900 a month in retirement without selling shares sounds clean until you see what the biggest position in this seven-ticker setup actually pays when markets go quiet.